<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03576690</url>
  </required_header>
  <id_info>
    <org_study_id>R3470-3471-3479-EBOV-1846</org_study_id>
    <nct_id>NCT03576690</nct_id>
  </id_info>
  <brief_title>R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus</brief_title>
  <official_title>Expanded Access Protocol for Emergency Use of REGN3470-3471-3479 for the Treatment of Ebola Virus Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Ebola Virus Disease</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REGN3470-3471-3479</intervention_name>
    <other_name>REGN-EB3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Males or females in an Ebola endemic region with documented positive polymerase chain
             reaction (PCR) for Ebola virus infection who are symptomatic

          -  Ability to provide informed consent personally or by a legal representative if the
             patient is unable to do so, based on local laws and regulations

          -  REGN-EB3 can be administered to pregnant women infected with Zaire ebolavirus, as
             defined in the protocol

          -  Children of any age will be eligible for enrollment, as defined in the protocol

          -  Neonates born to an infected mother who has not yet cleared the Ebola virus are
             eligible for enrollment, as defined in the protocol

        Key Exclusion Criteria:

          -  Negative EBOV diagnostic test result

          -  A patient who, in the judgment of the investigator, will be unlikely to comply with
             the requirements of this protocol

          -  Any serious medical condition that, in the opinion of the site investigator, would
             place the patient at an unreasonable increased risk through participation in this
             study, including any past or concurrent conditions

          -  Eligible for an ongoing randomized clinical trial with REGN-EB3

        NOTE: Other protocol defined inclusion / exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Positive Ebola Virus (EBOV) diagnostic test</keyword>
  <keyword>symptomatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

